Synlogic Therapeutics Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:$176.9M
Industry:Biotech
Founded:2014
Lead Investor(s):Leerink Partners

Industry Ranking

Estimated Revenue & Financials

  • Synlogic Therapeutics's estimated annual revenue is currently $13.8M per year.
  • Synlogic Therapeutics received $30.0M in venture funding in April 2018.
  • Synlogic Therapeutics's estimated revenue per employee is $155,000
  • Synlogic Therapeutics's total funding is $176.9M.

Employee Data

  • Synlogic Therapeutics has 89 Employees.
  • Synlogic Therapeutics grew their employee count by -5% last year.
  • Synlogic Therapeutics currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Ultivue
$8.7M56-12%N/AN/A
Ohana Bioscienc...
$8.7M5660%N/AN/A
Compass Therape...
$16.4M10614%N/AN/A
Cell Signaling ...
$89.4M577N/AN/AN/A
Momenta Pharmac...
N/A220N/AN/AN/A
Emulate
$15.3M99-17%N/AN/A
ArQule
N/A94N/AN/AN/A
Hamilton Storag...
$17.2M1119%N/AN/A
Alnylam Pharmac...
$74.9M127731%N/AN/A
Transgenomic
N/A47N/AN/AN/A
Missing a competitor? Contribute!?
Submit

At Synlogic, we are dedicated to bringing innovative medicines to patients by driving the convergence of two revolutionary fields: synthetic biology and the microbiome. Using our synthetic biotics platform, we are engineering probiotic bacteria to perform specific therapeutic functions with established links to disease. We can deliver these synthetic biotics orally, where they act from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. We also aim to deliver synthetic biotics at the site of disease in cases where local activity is critical, as in stimulation of immune effectors to combat certain tumors. We can rapidly translate this groundbreaking science and technology into medicines that have the potential to change the lives of patients. Our lead programs target patients with rare genetic metabolic diseases, including urea cycle disorders (UCD) and phenylketonuria (PKU). We are also hard at work on synthetic biotics to address more prevalent conditions, including inflammatory bowel disease (IBD), cancer and metabolic conditions such as diabetes and obesity. Learn more on our website at www.synlogictx.com.

keywords:Licensing,Biotechnology,Healthcare,Pharmaceuticals

89

Number of Employees

$13.8M

Revenue (est)

1

Current Jobs

-5%

Employee Growth %

$176.9M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Executive Contacts

NameTitleEmail
Chang HongCorporate Counsel & Head Of Intellectual Property
Aoife BrennanCeoEmail Available
Caroline KurtzSvp,head Of MetabolismEmail Available
Ning LiPrincipal ScientistEmail Available
Michael SlaterHead Of Regulatory Affairs
Brad SmithAssociate Director, Fp&a Lead
Kip WestDirector Of ImmunomodulationEmail Available
Katherine HeangIn Vivo Operations Manager
Philippa ReederUpstream Team Leader - Principal Scientist
Tracy KaneDirector, Interim Program Leader

Synlogic Therapeutics News

09/06/2019 - Synlogic Announces Appointments of New CMO, Head of ...

Synlogic, Inc. (SYBX), a clinical stage company applying synthetic ... its ability to advance these novel therapeutics into clinical trials,” stated Dr.

09/04/2019 - Synlogic Presents Data from Phase 1/2a Study of SYNB1618 ...

Synlogic has initiated a bridging study of a new solid formulation of ... to deliver novel medicines designed to perform a therapeutic function.”.

09/06/2019 - Synlogic (SYBX) Names New CMO, Head of Regulatory ...

Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying ... its ability to advance these novel therapeutics into clinical trials,” stated Dr.

Synlogic Therapeutics Funding

DateAmountRoundLead InvestorsReference
2014-10-08$5.0MABill & Melinda GatesArticle
2016-02-18$40.0MBOrbiMed HealthCare Fund ManagementArticle
2017-05-17$42.0MCMultipleArticle
2018-01-25$UndisclosedUndisclosedLeerink PartnersArticle
2018-04-09$30.0MUndisclosedLeerink PartnersArticle

Synlogic Therapeutics Executive Hires

DateNameTitleReference
2015-05-22Jose-Carlos Gutiérrez-RamosPresident/CEOArticle
2015-09-18Bharatt ChowriraPresidentArticle
2016-12-16Samantha TruexCOO /Head of Corporate Development.Article
2017-10-11Andrew GengosCOO/Head of Corporate DevelopmentArticle
2018-05-11Aoife BrennanInterim President/CEOArticle
2018-10-03Aoife BrennanPresident & CEOArticle
2018-12-13Antoine AwadHead of Technical OperationsArticle

Synlogic Therapeutics Acquisitions

DateCompany NameAmountNotesReference
2017-05-17Mirna Therapeutics Inc.Article
2017-08-29Mirna Therapeutics Inc.Article